Myeloproliferative Neoplasms (MPN)

- **CNL/atypical CML**
  - IRB# 10262: Oral Ruxolitinib for CNL or atypical CML.

- **Myelofibrosis**
  - IRB# 19142: Open-Label, Ph 2a/2b of KRT-232 in Subjects with Primary Myelofibrosis (MF), Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF who have failed prior treatment with a JAK Inhibitor.
  - IRB# 16363: Phase 2 INCBO50465 plus Ruxolitinib.

- **Systemic Mastocytosis**
  - IRB# 17155: Phase 1 of DCC-2618 in Advanced Malignancies.

- **Polycythemia vera**
  - IRB# 19144: 2-Part, Randomized, Open-label, Ph 2a/2b of KRT-232 Compared to Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera.
  - IRB# 15977: Non Treatment National MDS Study (ECOG/ACRIN).

- **Myelofibrosis**

http://www.ohsu.edu/research/rda/so/knight.php